Business Context and Reporting Period
This Form 8-K is filed by TRxADE HEALTH, INC. (Ticker: MEDS) on April 5, 2023. The report addresses the company's ongoing efforts to regain compliance with Nasdaq Capital Market listing requirements, specifically the minimum $2,500,000 stockholders' equity rule (Rule 5550(b)(1)).
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial metric referenced is the $2,500,000 minimum stockholders' equity requirement for continued listing. The company has proposed an underwritten public offering of up to $15,000,000 to address this deficiency.
Material Changes and Events
- Delisting Determination: On January 30, 2023, Nasdaq determined the company failed to meet the terms of a previous extension granted in October 2022.
- Hearing Outcome: Following a hearing on March 23, 2023, the Nasdaq Hearings Panel granted an exception on April 5, 2023, permitting continued listing while the company completes a public offering.
- Compliance Plan: The company's plan to regain compliance includes the proposed $15,000,000 offering and expense reductions.
Guidance, Outlook, and Risks
Conditions for Continued Listing:
- By April 15, 2023: The company must advise the Panel on the status of the S-1 registration statement filing.
- By June 21, 2023: The company must demonstrate compliance with the stockholders' equity rule.
Risks and Contingencies:
- There is no assurance the company will complete the offering or regain compliance.
- Delisting could result in reduced liquidity, difficulty in obtaining accurate stock quotations, and a material decline in stock price.
- Delisting may impair the company's ability to raise capital.
- Forward-looking statements are subject to risks including the ability to raise funding, going concern status, and strategic alternatives for the Bonum Health, Inc. subsidiary.
Investor Verification Checklist
- Verify the filing status of the S-1 registration statement by the April 15, 2023 deadline.
- Monitor the company's ability to close the proposed $15,000,000 public offering.
- Confirm compliance with the $2,500,000 stockholders' equity requirement by June 21, 2023.
- Review the Annual Report on Form 10-K for the year ended December 31, 2022, for detailed financial condition and going concern disclosures.